Young women (≤55 years) with acute myocardial infarction (AMI) have higher rates of morbidity and mortality than similarly aged men, but the reasons have yet to be identified. 1, 2 An adverse lipid profile is an important risk factor for cardiovascular outcomes after AMI, [3] [4] [5] and differences in lipid profile may account for sex differences in outcomes. However, little is known about whether young women and men with AMI have similar or distinct lipid profiles, particularly in an era of ubiquitous use of statins for secondary prevention. Understanding sex differences in post-AMI lipid profiles may provide important implications for treatment and guide strategies to reduce sex differences in outcomes.
Prior studies of post-AMI lipid profiles have been conducted in populations of predominately older patients. [6] [7] [8] [9] Thus, there is limited evidence about the lipid profiles in younger patients and in particular young women, who are known to be at increased risk for mortality compared with their male counterparts. 1, 2 Evidence from the general population suggests that young women have advantageous lipid profiles compared with men 10 ; however, it is unclear if lipid advantages persist after AMI. In addition, prior studies have focused on standard measurements, such as cholesterol and triglyceride, and did not collect information on lipoprotein subclasses. Given that lipoproteins encompass heterogeneous subclasses that vary in composition and physiological function, 11 a comprehensive characterization of lipids and lipoprotein subclasses in young women is needed to better understand a potential risk factor for long-term outcomes.
Importantly, differences in lipid profiles may reflect variation in treatment patterns, patients' health behaviors, comorbidity, and biological susceptibility. As one of the most important factors affecting lipid and lipoprotein levels, lipid-lowering therapy (predominately statins) is recommended by clinical guidelines to all AMI patients at hospital discharge. 12 Evidence suggests that women are less likely than men to receive guideline-recommended therapies and appear to be less adherent to medications. 13, 14 Compared with men, young women with AMI also tend to exercise less, smoke more, and have higher rates of diabetes and obesity-all factors that are strongly associated with lipid abnormalities after AMI. 1, 15 There has yet to be any explanation as to whether these factors are associated with differences in post-AMI lipid and lipoprotein profiles among young men and women.
To address these gaps in knowledge, we used data from Variation in Recovery: Role of Gender on Outcomes of Young AMI Patients (VIRGO), the largest prospective observational study of young men and women with AMI. 16 The objectives of this VIRGO analysis were (1) to characterize sex differences in lipid and lipoprotein profiles after hospital discharge among young men and women with AMI; (2) to describe use of statin and other lipid-lowering medications among young men and women with AMI; and (3) to assess the association between sex, patient characteristics, and post-AMI lipid profiles.
Methods
Participants and study design VIRGO has been described previously. 16 In brief, VIRGO was a prospective, observational study designed to investigate the demographic, clinical, psychosocial, biological, and behavioral factors associated with higher mortality in young women with AMI. 1, 2 For this analysis of post-AMI lipid and lipoprotein profile, we included participants who were between the ages of 18 and 55 and enrolled from 103 hospitals in the United States between August 21, 2008 , and January 5, 2012. Participants were recruited using a 2:1 female to male enrollment design to enrich the study's inclusion of young women.
The diagnosis of AMI was confirmed by increased cardiac biomarkers (with at least 1 cardiac biomarker above the 99th percentile of the upper reference limit) within 24 hours of admission. Additional evidence of acute myocardial ischemia was also required, including at least 1 of the following: symptoms of ischemia, electrocardiogram changes indicative of new ischemia, or imaging evidence of infarction. We excluded participants if they met any of the following criteria: previous enrollment in VIRGO, neither English nor Spanish speaking, unable to provide informed consent, development of elevated cardiac markers due to elective coronary revascularization, or AMI caused by physical trauma. 16 For this analysis, we also excluded participants who had missing lipid and lipoprotein data at 1 month after hospital discharge or who were lost to follow-up by 1 month, as well as samples with duplicate VIRGO IDs (Figure 1 ). Institutional review board approval was obtained at each participating institution, and participants provided informed consent for study participation including baseline hospitalization and follow-up interviews.
Data collection and variables
We collected baseline information on patients' sociodemographics, clinical presentation, and treatment from medical record abstraction and standardized in-person interviews administered by trained personnel during the index AMI admission. Follow-up telephone interviews and in-person blood tests were conducted at 1 month by the Yale Follow-Up Center.
At baseline, patients' serum lipid levels were derived from medical record abstraction. For 97% of patients, baseline serum lipid levels were obtained prior to arrival or within 24 hours of admission. At 1 month after hospital discharge, we measured serum lipids and lipoprotein subclasses by standardized assay. Specifically, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and triglyceride levels were measured by a blood draw according to standard procedures. Low-density lipoprotein cholesterol (LDL-C) was calculated by the Friedewald equation 17 if triglycerides were b400 mg/dL and was measured directly if triglycerides were ≥400 mg/dL. Lipoprotein subclasses were measured by a high-resolution ion mobility technique that physically separated lipoprotein particles by size. 18 These subclasses comprise the full spectrum of lipoprotein particles, including very low-density lipoprotein particle, intermediate-density lipoprotein particle, LDL particle, and HDL particle. We used the ion mobility technique to measure lipoprotein subclasses because it measures particle size accurately and counts the particles present at each size, providing a direct measurement of lipoprotein particle size and concentration for each lipoprotein subclass. 18 All serum lipids and lipoprotein subclasses were measured at Quest Diagnostics using the Beckman Coulter Olympus AU series instruments. The laboratory was certified by the National Heart, Lung, and Blood Institute and Centers for Disease Control and Prevention Lipid Standardization Program.
We obtained information on lipid-lowering medications at admission and discharge from medical records, and medications at 1 month from patient interviews. We identified patients who were taking high-intensity statins versus low-and moderate-intensity statins based on the type and dosage of statin therapy (Supplemental Table I ). High-intensity statins were defined as statins dosed at a level expected to lower LDL-C by at least 50% according to the American College of Cardiology/American Heart Association recommendation. 19 We also considered lipid-lowering therapies other than statins, including ezetimibe, niacin, fibrate, and fish oil.
We quantified patients' socioeconomic status by defining marital status, highest education, health insurance, employment status, and financial hardship (not having enough money to make ends meet or having just enough money to make ends meet vs having some money left over at the end of the month). We assessed the clinical severity of AMI presentations by final AMI diagnosis (ST-elevation AMI [STEMI]), left ventricular ejection fraction b40%, Global Registry of Acute Coronary Events (GRACE) risk score, 20 and length of hospital stay. We included other cardiac risk factors and comorbidities, such as menopausal status for women; physician diagnosis of hypertension, diabetes, dyslipidemia, and history of heart disease extracted from the medical record; obesity (body mass index ≥30 kg/m 2 ); prospectively measured waist circumference (high classified as N88 cm for women and N102 cm for men); smoking; and physical activity. Self-reported physical activity was measured with the Behavioral Risk Factor Surveillance Survey physical activity instrument, 21 which has high reliability and validity among young adults. 22 
Statistical analyses
Descriptive statistics of patient characteristics at baseline and 1 month were calculated for the overall population and compared between men and women. We calculated frequencies for categorical variables and medians with interquartile ranges for continuous variables. We determined statistical differences between women and men using χ 2 , Student t, and Wilcoxon rank sum tests, where appropriate.
To describe lipid and lipoprotein profile by sex, we estimated the distributions of various biomarkers for women and men separately. For the standard lipid profile, we plotted the distributions at baseline and 1 month by sex. We also compared the distributions at both periods in VIRGO with those in a nationally representative sample of the population in the United States based on the National Health and Nutrition Examination Survey (NHANES) 2011-2012. NHANES used a multistage, stratified, clustered probability sampling design and provided a representative sample of the noninstitutionalized population in the United States. 23 We included individuals aged 40-55 years (median age of 47) to have an age distribution similar to that of VIRGO. We accounted for the complex survey design in NHANES to make lipid estimates representative of the corresponding sex group in the national population. For lipoprotein subclasses, although the clinical thresholds have not yet been determined, we used a convenience sample of healthy employees from Quest Diagnostics as the reference population and compared their lipoprotein subclasses with those in VIRGO. This sample consisted of volunteers who were aged 18-66 years (median age of 28 for men and 34 for women), had no history of heart disease or diabetes, and were not on heart-related medications.
To further examine the association of sex, clinical characteristics, and lipoprotein biomarkers, we conducted multivariable linear regression analyses. We considered LDL-C, HDL-C, TC/HDL-C ratio, HDL large particle, LDL small particle, and lipoprotein (a) as the dependent variables because they are known to be strong predictors of cardiovascular outcomes. 24 Explanatory variables included patient sex, age, race, marital status, employment, AMI type, diabetes and obesity at baseline, smoking, physical activity, and statin use at 1 month. We did not include menopausal status in the model because this variable was applicable only to women and missing for men. For each dependent variable, 2 models were developed: model 1 included sex only, and model 2 included sex and all other covariates. We also tested the interactions between sex and diabetes on each lipid parameter. We considered a 2-sided P b .05 as statistically significant. All analyses were conducted with SAS 9.3 (SAS Institute Inc, Cary, NC) and the most recent version of the VIRGO database.
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Results

Sample characteristics
There were 2,219 adults with AMI in VIRGO included in this analysis (725 men and 1,494 women; Figure 1 ). The median age was similar for both sexes (48 years for men and 49 years for women). The majority of patients were white (78%), were married (52%), had more than a high school education (59%), and had health insurance (79%). About half presented with STEMI, and one-third had prior heart disease. Cardiovascular risk factors (eg, hypertension, diabetes, dyslipidemia, and obesity) were common in these patients (Table I) .
Compared with men, women were more likely to be black; be single; and have diabetes mellitus, obesity, high waist circumference, prior stroke, congestive heart failure, and longer wait times from symptom onset of AMI to hospital arrival, but were less likely to have dyslipidemia and present with STEMI. The clinical severity of the AMI was similar for men and women: 8.5% of men and 9.1% of women had a GRACE risk score N99 (P = .66). There were 10.0% of men and 10.1% of women with an ejection fraction b40% (P = .91). Nearly half of the women were postmenopausal, of which 2.3% used estrogen therapy.
At 1-month follow-up, women were more likely to be unemployed and have not enough money to make ends meet compared with men (Table II) . In addition, women were more likely to be current smokers and to be physically inactive.
Lipid-lowering medications on admission, at discharge, and at 1 month One-third of adults hospitalized with AMI were already treated with statins at admission; this proportion increased to N90% at discharge (Table III) . Less than 3% of patients had a contraindication to statins. Among adults treated with statins, 42.7% were on high-intensity statins and 57.3% were on low-and moderate-intensity statins. At 1 month after discharge for AMI, statin use decreased; 12.3% of adults (11.1% of women and 12.9% of men, P = .25) were no longer taking statins. As a result, approximately 1 in 5 adults (17.6%) was not on a statin at 1 month after discharge.
Compared with men, women had similar use of any statins on admission (30.3% vs 31.6%, P = .52) and at 1 month (80.6% vs 86.1%, P = .08) but had slightly less use at discharge (90.1% vs 95.4%, P =.03). Among those on statins, women were less likely to report being treated with a high-intensity dose at 1 month (39.0% vs 45.1%, P = .02), but the absolute differences were modest (6 percentage points).
Sex differences in lipids and lipoprotein subclasses at baseline and 1 month
At baseline, TC and LDL-C levels were similar between men and women and were slightly lower than the levels in the US general population (Supplemental Table II) . Even for adults not treated with statins on admission (70% of the cohort), the LDL-C level was lower than that of the general population (median of 112 mg/dL vs 122 mg/dL, results not shown). The baseline HDL-C level was very low for both sexes, with medians ≤40 mg/dL. Because of the low HDL-C levels, the ratios of TC to HDL-C were higher for both sexes compared with those of the general population. Figure 2 shows how the distributions of lipid biomarkers changed between baseline and 1-month post-AMI by sex. There were substantial reductions in TC and LDL-C levels between baseline and 1 month for both men and women but only minimal change in HDL-C and triglyceride levels ( Figure 2 ). The reductions in TC and LDL-C levels were smaller in women than in men (median reduction of 10% vs 13% for TC and 11% vs 16% for LDL-C, results not shown).
At 1 month, TC and LDL-C had been reduced to low levels in both men and women: the median (interquartile range) of TC was 145 (126-174) mg/dL for men and 157 (132-185) mg/dL for women, whereas LDL-C was 81 (65-104) mg/dL for men and 86 (67-107) mg/dL for women (Supplemental Table II) . These values were substantially lower than those in the similarly aged general population. HDL-C levels remained very low for both sexes (33 [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] The results of lipoprotein subclasses generally paralleled these findings and showed statistically significant sex differences. The concentrations of LDL particles (total and all subclasses) in VIRGO were lower compared with those of the sample of healthy volunteers for both men and women (Supplemental Table III ). This was consistent with the finding of low LDL-C levels. Similarly, the concentrations of HDL particles were also lower in VIRGO and consistent with the finding of low HDL-C levels. Compared with men, women had higher concentrations of total HDL particles because of higher concentrations of large and small HDL subclasses. However, despite a slightly higher LDL-C level for women, there were no sex differences in the concentration of total LDL particles (1221 [972-1570] nmol/L for men and 1205 [961-1525] nmol/L for women, P = .45). This is because women had higher concentrations of large LDL particles but lower concentrations of small and very small LDL particles compared with men. The median LDL particle size for women was slightly larger than that for men.
Sex, patient characteristics, and lipid and lipoprotein profiles at 1 month
Fully adjusted analyses demonstrated that young women had slightly favorable lipid and lipoprotein profiles compared with men. Women had higher levels of HDL-C and HDL large particle but had lower levels of TC/HDL-C ratio and LDL small particle than men in the unadjusted models (Table IV) . These sex differences persisted even after adjusting for sociodemographic and clinical characteristics (P b .05 for all). The higher LDL-C level in women in the unadjusted model was no longer significant in the fully adjusted model. The difference in LDL-C levels was explained largely by differences in statin use, sociodemographic factors, and comorbidities. A lower level of HDL-C at 1 month was associated with younger age, male sex, white race, receiving high-intensity statins, being unemployed, having comorbidities and unhealthy lifestyles (diabetes, obesity, smoking, and physical inactivity), and STEMI. We also tested the interactions between diabetes and sex for all 6 models presented in Table IV . A significant sex by diabetes interaction was found only for the model of LDL small particle (P = .0002): having diabetes was significantly associated with higher concentration of LDL small particle in women (estimate of 33.61; P b .001) but All percentages were calculated by excluding missing, do not know, and patient refused. ⁎ This shows the number of patients taking only nonstatin therapy so that the numbers of statin and nonstatin therapy sum up to the total sample. If a patient takes both statin and nonstatin therapy at the same time, he/she would be counted in the "statin" category. † Thirty-six patients who were not prescribed statin at discharge were on statin at 1 month. 
Women
Distributions of standard lipid profile at baseline hospitalization and at 1 month after discharge for AMI, by sex (baseline = blue, 1 month = red). LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol.
not in men (estimate of −12.15; P = .23). Nondiabetic women had lower concentration of LDL small particle than nondiabetic men (estimate of −66.12; P b .001), but there was no significant sex difference for diabetic individuals (estimate of −20.35; P = .15).
Discussion
In this large study of young adults with AMI, we found small sex differences in lipid biomarkers. Women had slightly favorable lipid and lipoprotein profiles compared with men at baseline hospitalization and at 1 month The models were developed based on cohorts that excluded missing values in all variables. LDL, low-density lipoprotein; HDL, high-density lipoprotein; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TC/HDL-C ratio, total cholesterol-to-high-density lipoprotein cholesterol ratio.
post-AMI. More than 90% of adults were discharged on a statin, but less than half received a high-intensity dose. Treatment decreased at 1 month, and about 1 in 5 patients was not on statins at 1 month after discharge for AMI. For most men and women, LDL-C levels were reduced to b100 mg/dL by 1 month, but the low HDL-C of b40 mg/dL was a major lipid abnormality. Our finding of slightly favorable lipid profiles in women compared with men allowed us to exclude the hypothesis that a high-risk lipid pattern explains why young women with AMI have higher mortality than men. Even our comprehensive assessment of lipoprotein subclasses showed favorable profiles in women, adding to the evidence that lipoprotein abnormality may not be a major contributor to sex difference in outcomes. The favorable lipid and lipoprotein profiles in women were only partially explained by sociodemographic and clinical confounders and remained statistically significant in the fully adjusted model. The unexplained differences might be caused by other factors not analyzed here such as genetic variants associated with lipoprotein subclass distributions and response to statins. 25 Our analysis of lipid-lowering treatment suggests that statin was inadequately used in both men and women. We found that more than half of patients were not prescribed high-intensity statins at discharge even though it is recommended in guidelines for all AMI patients. 19 A potential reason could be that the baseline LDL-C levels of these young patients were not high enough (median of b110 mg/dL) and physicians may consider low-or moderate-intensity statins sufficient. Consistent with previous studies, 13 we also found that a significant proportion of patients discontinued statin treatment by 1 month with no appreciable difference between men and women. It is possible that patients with lower education level, lack of health insurance, or lack of money to pay for medications were more likely to stop treatments, 14, 26 resulting in a decrease in treatment adherence. It is also possible that the LDL-C level has been substantially reduced to b100 mg/dL at 1 month and physicians still consider treating LDL-C according to target levels as opposed to the patient's overall risk (as endorsed by the recent American College of Cardiology/American Heart Association guideline). 19 Furthermore, our findings of the low HDL-C levels of b40 mg/dL in both men and women raise concern. Several clinical trials have identified a low HDL-C level as an independent predictor of major cardiovascular events in patients treated with statins. 27, 28 This relationship remains significant even among patients with LDL-C b70 mg/dL. 28 However, whether increasing HDL-C level could translate into benefits of cardiovascular outcomes is still uncertain. Recent randomized clinical trials showed that effective agents for increasing HDL-C levels, such as niacin, fibrates, and cholesteryl ester transfer protein inhibitors, failed to reduce mortality and cardiovascular outcomes when statin treatment was already in place.
29-31
The mechanism is not clear, but a number of explanations have been proposed. For example, the overall HDL-C level alone may be an inadequate marker for lipoprotein functionality, and certain HDL subfractions may be more important determinants of cardiovascular risk. 31 This article contributes to the literature in several key ways. First, it is the largest comprehensive analysis of sex differences in lipid and lipoprotein profiles in young adults with AMI. Previous studies were based predominantly on elderly individuals and only included sex as a covariate in the model rather than explicitly addressing sex differences in lipid profile as the primary objective. Second, our comprehensive evaluation of lipoprotein subclasses adds to our understanding of the subclass profiles in young adults with AMI. Previous studies focused on standard measurements (eg, cholesterol and triglyceride), [6] [7] [8] [9] which alone may have been insufficient to reveal other markedly different patterns in this population. Finally, we are able to identify the pattern of lipid-lowering treatment in men and women on admission, at discharge, and at 1 month.
Our study has important implications for treatment of young women with AMI. As a majority of women did not receive high-intensity statins at discharge and medication adherence remained suboptimal, targeted interventions to promote statin use and adherence are needed to reduce cardiovascular risk in this population. In addition, substantial residual risks persist in women with AMI despite LDL-C levels being well controlled after discharge. 32 This underscores the importance of treating patients according to their overall cardiovascular risks rather than LDL-C target alone. As residual risks in young women are affected by multiple factors, improving outcomes in this population may require risk modification that extends beyond LDL lowering with a combination of medications and lifestyle interventions. These efforts might include adding medications such as high-intensity statins, antiplatelet agents, β-blockers, and angiotensin-converting enzyme inhibitors, as well as smoking cessation, physical activity, and improvement in other factors that have impaired outcomes in these patients.
There are some limitations to this study. First, VIRGO was an observational study that required patients to be healthy enough at baseline to participate; thus, we were unable to capture those who were too ill to be enrolled. Second, baseline serum lipid levels were extracted from medical records rather than measured according to standard protocol. However, the lipid levels for 97% of patients were obtained before arrival to the hospital or within 24 hours of admission, which is consistent with the Adult Treatment Panel III guidelines of using the initial (b24 hours after admission) LDL values to guide therapy. 33 The evidence on lipid stability after AMI is mixed, but many studies suggest that lipid profiles within 24 hours of admission are not influenced or only influenced to a limited degree by the acute phase reaction and so should be representative of the patients' typical levels. 6, [34] [35] [36] Third, we did not measure lipoprotein subclasses at baseline and were unable to examine change in lipoprotein subclasses during follow-up. It is possible that atherogenic lipoproteins at 1 month have been eliminated because of statin treatment after the AMI event. Fourth, we used data from a convenience sample of healthy employees as the reference ranges for lipoprotein subclasses, which might limit the interpretability of our results for subclasses. Finally, our measure of statin adherence is indirect because we calculated adherence by comparing the difference in treatment rates at discharge and 1 month. This approach may overestimate adherence in patients who did not take medications between the 2 periods.
In conclusion, young women with AMI had slightly favorable lipid and lipoprotein profiles compared with similarly aged men, suggesting that difference in lipids and lipoproteins may not be a major contributor to the sex differences in outcomes among young adults with AMI. In both men and women, statin remained inadequately used, and low HDL-C level was a major lipid abnormality.
